SILVERARC CAPITAL MANAGEMENT, LLC
13F Reported Value
ⓘ$979.8M
incl. option notional
Equity Holdings
ⓘ$848.6M
Option Notional
ⓘ$131.2M
$105.4M puts / $25.8M calls
Holdings
73
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
SILVERARC CAPITAL MANAGEMENT, LLC disclosed 73 positions worth $979.8M in its Form 13F-HR for Q1 2026 — $848.6M in common stock plus $131.2M of put/call option positions (reported at underlying notional value, not premium at risk), followed by $KALV and $DNTH. During the quarter the fund opened 25 new positions and exited 20 and a full exit from $VRDN. The portfolio is most concentrated in Healthcare (98.5% of disclosed assets). All figures are sourced directly from SILVERARC CAPITAL MANAGEMENT, LLC’s Form 13F-HR filing with the SEC under CIK 1816307.
AI Fund Analysis
DiversifyingSector Allocation
AUM History
Top Equity Holdings by Value
Option Positions
13F rules report options at the value of the underlying shares (notional) — not the premium paid or capital at risk. Shown separately from the equity sleeve above.
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
SPDR SERIES TRUST PUT
—Quality
$105.4M825,000 sh- 25.9#2,530
Quality
$57.9M2,876,407 sh - 26.8#2,490
Quality
$54.9M654,746 sh - —
Quality
$50.6M1,314,189 sh - —
Quality
$40.9M357,903 sh - 5.8
Quality
$40.5M1,850,278 sh - —
Quality
$37.8M991,930 sh - —
Quality
$36.4M354,914 sh - —
Quality
$33.7M302,530 sh - 18.1
Quality
$32.9M2,002,040 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
| SPDR SERIES TRUST PUT | — | $105.4M | 825,000 |
 KalVista Pharmaceuticals, Inc.$KALV | 25.9#2,530 | $57.9M | 2,876,407 |
 Dianthus Therapeutics, Inc. /DE/$DNTH | 26.8#2,490 | $54.9M | 654,746 |
 Cogent Biosciences, Inc.$COGT | — | $50.6M | 1,314,189 |
 Celcuity Inc.$CELC | — | $40.9M | 357,903 |
 Immunome Inc.$IMNM | 5.8 | $40.5M | 1,850,278 |
 Kodiak Sciences Inc.$KOD | — | $37.8M | 991,930 |
 Nuvalent, Inc.$NUVL | — | $36.4M | 354,914 |
 Abivax S.A.$ABVX | — | $33.7M | 302,530 |
 Monte Rosa Therapeutics, Inc.$GLUE | 18.1 | $32.9M | 2,002,040 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of SILVERARC CAPITAL MANAGEMENT, LLC's 73 positions.
Showing top 10 of 73 holdings.
Sector Allocation
Healthcare
$836.4M
Other
$12.3M
Full Holdings — SILVERARC CAPITAL MANAGEMENT, LLC (Q1 2026)
All 73 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | — | SPDR SERIES TRUST | $105.4M | — | NEW | — |
| 2 | $KALV | KalVista Pharmaceuticals, Inc. | $57.9M | 6.8% | +19% | 25.9 |
| 3 | $DNTH | Dianthus Therapeutics, Inc. /DE/ | $54.9M | 6.5% | -13% | 26.8 |
| 4 | $COGT | Cogent Biosciences, Inc. | $50.6M | 6.0% | +6% | — |
| 5 | $CELC | Celcuity Inc. | $40.9M | 4.8% | -5% | — |
| 6 | $IMNM | Immunome Inc. | $40.5M | 4.8% | +64% | 5.8 |
| 7 | $KOD | Kodiak Sciences Inc. | $37.8M | 4.5% | -3% | — |
| 8 | $NUVL | Nuvalent, Inc. | $36.4M | 4.3% | +14% | — |
| 9 | $ABVX | Abivax S.A. | $33.7M | 4.0% | -28% | — |
| 10 | $GLUE | Monte Rosa Therapeutics, Inc. | $32.9M | 3.9% | +95% | 18.1 |
| 11 |  $ERAS | Erasca, Inc. | $30.0M | 3.5% | +41% | — |
| 12 |  $ASND | Ascendis Pharma A/S | $28.5M | 3.4% | +153% | 41.5 |
| 13 |  $URGN | UroGen Pharma Ltd. | $27.0M | 3.2% | -14% | — |
| 14 |  $RYTM | RHYTHM PHARMACEUTICALS, INC. | $26.6M | 3.1% | +125% | 30.3 |
| 15 |  $PRAX | Praxis Precision Medicines, Inc. | $23.1M | 2.7% | -13% | — |
| 16 |  $ZBIO | Zenas BioPharma, Inc. | $22.2M | 2.6% | NEW | 14.4 |
| 17 |  $SNDX | Syndax Pharmaceuticals Inc | $20.8M | 2.5% | +38% | 30 |
| 18 |  $CNTA | Centessa Pharmaceuticals plc | $18.5M | 2.2% | +2% | — |
| 19 |  $SRRK | Scholar Rock Holding Corp | $16.7M | 2.0% | NEW | — |
| 20 |  $ALKS | Alkermes plc. | $16.3M | 1.9% | NEW | — |
| 21 |  $ORIC | Oric Pharmaceuticals, Inc. | $13.9M | 1.6% | -1% | — |
| 22 |  $IRON | Disc Medicine, Inc. | $12.5M | 1.5% | NEW | — |
| 23 | — | HELIX ACQUISITION CORP III | $12.3M | 1.4% | NEW | — |
| 24 |  $XENE | Xenon Pharmaceuticals Inc. | $11.5M | 1.4% | NEW | 12.9 |
| 25 |  $CGON | CG Oncology, Inc. | $11.3M | 1.3% | -54% | 28 |
| 26 |  $IMVT | Immunovant, Inc. | $10.3M | 1.2% | NEW | — |
| 27 |  $SYRE | Spyre Therapeutics, Inc. | $9.4M | 1.1% | -1% | — |
| 28 |  $BIIB | BIOGEN INC. | $9.3M | 1.1% | -32% | 65.6 |
| 29 |  $GH | Guardant Health, Inc. | $9.1M | 1.1% | +7% | 36.1 |
| 30 |  $PCVX | Vaxcyte, Inc. | $8.4M | 1.0% | -3% | — |
| 31 |  $QURECALL | uniQure N.V. | $8.2M | — | -31% | — |
| 32 |  $SVRA | Savara Inc | $7.8M | 0.9% | NEW | — |
| 33 |  $BNTC | Benitec Biopharma Inc. | $7.6M | 0.9% | -2% | — |
| 34 | $SNDXCALL | Syndax Pharmaceuticals Inc | $7.5M | — | NEW | 30 |
| 35 |  $ORKA | Oruka Therapeutics, Inc. | $7.4M | 0.9% | NEW | — |
| 36 |  $CGEN | COMPUGEN LTD | $7.1M | 0.8% | -5% | — |
| 37 | $CELCCALL | Celcuity Inc. | $6.2M | — | NEW | — |
| 38 |  $TRVI | Trevi Therapeutics, Inc. | $6.1M | 0.7% | -6% | — |
| 39 |  $INSM | INSMED Inc | $5.9M | 0.7% | -50% | 29.4 |
| 40 |  $VCYT | VERACYTE, INC. | $5.8M | 0.7% | -50% | 59.5 |
| 41 |  $CERS | CERUS CORP | $5.8M | 0.7% | +13% | 29.3 |
| 42 |  $CLDX | Celldex Therapeutics, Inc. | $5.7M | 0.7% | -7% | 13.2 |
| 43 |  $CCCC | C4 Therapeutics, Inc. | $5.0M | 0.6% | -4% | 6.5 |
| 44 |  $CYTK | CYTOKINETICS INC | $4.7M | 0.6% | NEW | 28 |
| 45 |  $CLYM | Climb Bio, Inc. | $4.7M | 0.6% | NEW | — |
| 46 |  $CMPX | Compass Therapeutics, Inc. | $4.5M | 0.5% | -18% | — |
| 47 |  $SRZN | Surrozen, Inc./DE | $4.2M | 0.5% | -8% | — |
| 48 |  $CTNM | Contineum Therapeutics, Inc. | $3.9M | 0.5% | -2% | — |
| 49 |  $ZURA | Zura Bio Ltd | $3.3M | 0.4% | NEW | — |
| 50 |  $FULC | Fulcrum Therapeutics, Inc. | $3.2M | 0.4% | +6% | — |
| 51 | $FULCCALL | Fulcrum Therapeutics, Inc. | $3.0M | — | +0% | — |
| 52 |  $ABEO | ABEONA THERAPEUTICS INC. | $2.9M | 0.3% | +3% | 44.3 |
| 53 |  $CAMP | Camp4 Therapeutics Corp | $2.9M | 0.3% | NEW | 23.3 |
| 54 |  $ANNX | Annexon, Inc. | $2.8M | 0.3% | NEW | — |
| 55 |  $ELUT | ELUTIA INC. | $2.6M | 0.3% | -9% | — |
| 56 |  $CBIO | CRESCENT BIOPHARMA, INC. | $2.4M | 0.3% | NEW | 28 |
| 57 |  $MNPR | Monopar Therapeutics | $2.4M | 0.3% | NEW | — |
| 58 |  $OVID | Ovid Therapeutics Inc. | $2.2M | 0.3% | NEW | 13.1 |
| 59 |  $NXTC | NextCure, Inc. | $1.9M | 0.2% | +0% | — |
| 60 |  $CMPS | COMPASS Pathways plc | $1.7M | 0.2% | NEW | — |
| 61 |  $NMRA | Neumora Therapeutics, Inc. | $1.6M | 0.2% | NEW | — |
| 62 |  $SION | Sionna Therapeutics, Inc. | $1.6M | 0.2% | -5% | — |
| 63 |  $TELA | TELA Bio, Inc. | $1.4M | 0.2% | -15% | 24.9 |
| 64 |  $EWTX | Edgewise Therapeutics, Inc. | $1.3M | 0.2% | +1% | — |
| 65 |  $REPL | Replimune Group, Inc. | $1.3M | 0.1% | NEW | — |
| 66 |  $GENB | Generate Biomedicines, Inc. | $1.3M | 0.1% | NEW | — |
| 67 | $CMPXCALL | Compass Therapeutics, Inc. | $911,996 | — | NEW | — |
| 68 |  $RADX | Radiopharm Theranostics Ltd | $805,846 | 0.1% | +0% | — |
| 69 |  $GUTS | FRACTYL HEALTH, INC. | $779,004 | 0.1% | -83% | — |
| 70 |  $IBIO | iBio, Inc. | $429,400 | 0.1% | +113% | — |
| 71 |  $ADGM | Adagio Medical Holdings, Inc. | $289,768 | 0.0% | -51% | — |
| 72 |  $AARD | Aardvark Therapeutics, Inc. | $126,989 | 0.0% | -89% | — |
| 73 |  $RCKT | ROCKET PHARMACEUTICALS, INC. | $2,159 | 0.0% | +0% | — |
New Positions (25)
$ZBIO Zenas BioPharma, Inc.$22.2M$SRRK Scholar Rock Holding Corp$16.7M$ALKS Alkermes plc.$16.3M$IRON Disc Medicine, Inc.$12.5M$XENE Xenon Pharmaceuticals Inc.$11.5M$IMVT Immunovant, Inc.$10.3M$SVRA Savara Inc$7.8M$SNDXCALL Syndax Pharmaceuticals Inc$7.5M$ORKA Oruka Therapeutics, Inc.$7.4M$CELCCALL Celcuity Inc.$6.2M$CYTK CYTOKINETICS INC$4.7M$CLYM Climb Bio, Inc.$4.7M$ZURA Zura Bio Ltd$3.3MExited Positions (20)
$VRDN Viridian Therapeutics, Inc.\DE
$PFE PFIZER INC
$AVTX Avalo Therapeutics, Inc.
$GOSS Gossamer Bio, Inc.
$LXEO Lexeo Therapeutics, Inc.
$AMLX Amylyx Pharmaceuticals, Inc.
$SLNO SOLENO THERAPEUTICS INC
$OLMA Olema Pharmaceuticals, Inc.$KALVCALL KalVista Pharmaceuticals, Inc.
$MLYS Mineralys Therapeutics, Inc.
$RLAY Relay Therapeutics, Inc.$QURE uniQure N.V.
$TARS Tarsus Pharmaceuticals, Inc.
$KYMR Kymera Therapeutics, Inc.Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for SILVERARC CAPITAL MANAGEMENT, LLC including:
Track SILVERARC CAPITAL MANAGEMENT, LLC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for SILVERARC CAPITAL MANAGEMENT, LLC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: SILVERARC CAPITAL MANAGEMENT, LLC
13F Pro is an AI hedge fund tracker and stock research platform. For SILVERARC CAPITAL MANAGEMENT, LLC (SEC CIK: 1816307), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in SILVERARC CAPITAL MANAGEMENT, LLC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.